Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
102.414,79
0,00%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM) Notizie

ATNM

Actinium Pharmaceuticals (ATNM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:ATNM
DataOraFonteTitoloSimboloCompagnia
27/11/202422:30Edgar (US Regulatory)Form 8-K - Current reportAMEX:ATNMActinium Pharmaceuticals Inc
18/11/202414:00PR Newswire (US)Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024AMEX:ATNMActinium Pharmaceuticals Inc
14/11/202422:57Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:ATNMActinium Pharmaceuticals Inc
09/11/202400:51Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
06/11/202413:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:ATNMActinium Pharmaceuticals Inc
05/11/202423:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
05/11/202423:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:ATNMActinium Pharmaceuticals Inc
05/11/202423:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:ATNMActinium Pharmaceuticals Inc
04/11/202413:30PR Newswire (US)Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of DirectorsAMEX:ATNMActinium Pharmaceuticals Inc
20/09/202414:00PR Newswire (US)Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical OncologyAMEX:ATNMActinium Pharmaceuticals Inc
05/08/202413:00PR Newswire (US)Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.AMEX:ATNMActinium Pharmaceuticals Inc
01/08/202414:00PR Newswire (US)Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant IndicationsAMEX:ATNMActinium Pharmaceuticals Inc
25/07/202414:45PR Newswire (US)Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia UniversityAMEX:ATNMActinium Pharmaceuticals Inc
25/07/202413:30PR Newswire (US)Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit USAMEX:ATNMActinium Pharmaceuticals Inc
17/06/202414:00PR Newswire (US)Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA CongressAMEX:ATNMActinium Pharmaceuticals Inc
14/06/202414:30PR Newswire (US)Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA TrialAMEX:ATNMActinium Pharmaceuticals Inc
11/06/202414:30PR Newswire (US)Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
10/06/202414:30PR Newswire (US)Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
15/05/202414:30PR Newswire (US)Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market OpportunityAMEX:ATNMActinium Pharmaceuticals Inc
15/05/202400:38PR Newswire (US)Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the PhasAMEX:ATNMActinium Pharmaceuticals Inc
13/05/202414:30PR Newswire (US)Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
07/05/202414:00PR Newswire (US)Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas SouthwesternAMEX:ATNMActinium Pharmaceuticals Inc
18/04/202414:00PR Newswire (US)Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual MeetingAMEX:ATNMActinium Pharmaceuticals Inc
01/04/202414:00PR Newswire (US)Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant AnnualAMEX:ATNMActinium Pharmaceuticals Inc
26/03/202412:18PR Newswire (US)Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell TherapyAMEX:ATNMActinium Pharmaceuticals Inc
11/03/202412:30PR Newswire (US)Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market DemandAMEX:ATNMActinium Pharmaceuticals Inc
26/02/202413:30PR Newswire (US)Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTAMEX:ATNMActinium Pharmaceuticals Inc
23/02/202413:30PR Newswire (US)Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBAMEX:ATNMActinium Pharmaceuticals Inc
09/02/202422:30Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:ATNMActinium Pharmaceuticals Inc
06/02/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:ATNMActinium Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:AMEX:ATNM

La tua Cronologia

BIT
STMMI
ST Microelectronics
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
G
Generali
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
ENEL
Enel
BIT
PRY
Prysmian
BIT
CPR
Davide Campari
BIT
BAMI
Banco BPM
BIT
IVG
Iveco Group NV
BIT
SPM
Saipem
BIT
MONC
Moncler
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci